Brief: Hofseth Biocare Transfers Eosinophil-Targeting Drug Candidate To Subsidiary
July 2 (Reuters) - Hofseth Biocare ASA HBC.OL :
* DECIDE TO TRANSFER ITS EOSINOPHIL-TARGETING DRUG CANDIDATE
MA-022A TO ITS MAJORITY-OWNED SUBSIDIARY HBC IMMUNOLOGY INC
Source text for Eikon: ID:nObijQWFka
Further company coverage: HBC.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hofseth Biocare ASA
See all newsBrief: Hofseth BioCare Board Member Buys 2.5 Mln Shares in Company
Brief: Hofseth Biocare Appoints Leif Arne Giske As CFO
Hofseth BioCare Q2 operating revenue slips on lower raw material volumes
Brief: Hofseth Biocare Q2 Revenue NOK 65.7 Million
Brief: Research Corporation Buys 14.3 Mln Shares In Hofseth Biocare